TABLE 3.

Best radiological response evaluated per RECIST criteria version 1.1

Atezolizumab plus Bevacizumab	Overall Population (n = 174 a )	CP‐A (n = 140)	CP‐B (n = 34)
ORR b , %	25%	26%	21%
DCR c , %	73%	74%	68%
CR	1%	1%	0
PR	24%	25%	21%
SD	48%	48%	47%
Progressive disease	27%	26%	32%

^a Radiological response was available for 174 patients (86% of the efficacy population).

^b ORR was considered as the sum of complete and partial responses.

^c DCR was considered as the sum of complete and partial responses and SD.